Switch to:
Also traded in: Belgium, Germany, Netherlands, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt 34109.73
GLPG's Cash-to-Debt is ranked higher than
100% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. GLPG: 34109.73 )
Ranked among companies with meaningful Cash-to-Debt only.
GLPG' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.96  Med: 351.59 Max: 34109.73
Current: 34109.73
2.96
34109.73
Equity-to-Asset 0.78
GLPG's Equity-to-Asset is ranked higher than
52% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GLPG: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
GLPG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.68  Med: 0.73 Max: 0.91
Current: 0.78
0.68
0.91
Interest Coverage No Debt
GLPG's Interest Coverage is ranked lower than
54% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GLPG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GLPG' s Interest Coverage Range Over the Past 10 Years
Min: 0.66  Med: 1.5 Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 9.39
Beneish M-Score: -1.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -13.22
GLPG's Operating Margin % is ranked higher than
68% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. GLPG: -13.22 )
Ranked among companies with meaningful Operating Margin % only.
GLPG' s Operating Margin % Range Over the Past 10 Years
Min: -226.08  Med: -18.64 Max: 1.78
Current: -13.22
-226.08
1.78
Net Margin % -18.11
GLPG's Net Margin % is ranked higher than
73% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. GLPG: -18.11 )
Ranked among companies with meaningful Net Margin % only.
GLPG' s Net Margin % Range Over the Past 10 Years
Min: -299.29  Med: -7.37 Max: 47.88
Current: -18.11
-299.29
47.88
ROE % -3.42
GLPG's ROE % is ranked higher than
76% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. GLPG: -3.42 )
Ranked among companies with meaningful ROE % only.
GLPG' s ROE % Range Over the Past 10 Years
Min: -41.46  Med: -5.25 Max: 17.79
Current: -3.42
-41.46
17.79
ROA % -2.44
GLPG's ROA % is ranked higher than
77% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. GLPG: -2.44 )
Ranked among companies with meaningful ROA % only.
GLPG' s ROA % Range Over the Past 10 Years
Min: -33.22  Med: -2.99 Max: 11.91
Current: -2.44
-33.22
11.91
ROC (Joel Greenblatt) % 302.29
GLPG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. GLPG: 302.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GLPG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1001.81  Med: -60.5 Max: 377.78
Current: 302.29
-1001.81
377.78
3-Year Revenue Growth Rate 0.90
GLPG's 3-Year Revenue Growth Rate is ranked lower than
55% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. GLPG: 0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GLPG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40  Med: 3.9 Max: 40
Current: 0.9
-40
40
GuruFocus has detected 2 Warning Signs with Galapagos NV $GLPG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GLPG's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GLPG Guru Trades in Q3 2016

Jim Simons 140,200 sh (+1630.86%)
» More
Q4 2016

GLPG Guru Trades in Q4 2016

Eaton Vance Worldwide Health Sciences Fund 99,828 sh (New)
Jim Simons 205,500 sh (+46.58%)
» More
Q1 2017

GLPG Guru Trades in Q1 2017

Jim Simons 311,200 sh (+51.44%)
Eaton Vance Worldwide Health Sciences Fund 99,828 sh (unchged)
» More
Q2 2017

GLPG Guru Trades in Q2 2017

Frank Sands 2,138,491 sh (New)
Jim Simons 465,300 sh (+49.52%)
Eaton Vance Worldwide Health Sciences Fund 99,828 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with GLPG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:XBRU:ABLX, XBRU:CYAD, XBRU:TIG, XBRU:MDXH, XBRU:THR, XBRU:BOTHE, XBRU:ASIT, XBRU:TUBAT, XBRU:UCB » details
Traded in other countries:GLPG.Belgium, GXE.Germany, GLPG.Netherlands, 0JXZ.UK, GLPGF.USA,
Headquarter Location:Belgium
Galapagos NV is a clinical-stage biotechnology company. It is engaged in the discovery and development of small molecule medicines which address unmet medical conditions.

Galapagos is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Ratios

vs
industry
vs
history
PB Ratio 3.93
GLPG's PB Ratio is ranked lower than
51% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. GLPG: 3.93 )
Ranked among companies with meaningful PB Ratio only.
GLPG' s PB Ratio Range Over the Past 10 Years
Min: 2.03  Med: 3.7 Max: 6.18
Current: 3.93
2.03
6.18
PS Ratio 26.47
GLPG's PS Ratio is ranked lower than
63% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. GLPG: 26.47 )
Ranked among companies with meaningful PS Ratio only.
GLPG' s PS Ratio Range Over the Past 10 Years
Min: 12.29  Med: 26.55 Max: 57.81
Current: 26.47
12.29
57.81
EV-to-EBIT 64.03
GLPG's EV-to-EBIT is ranked lower than
73% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. GLPG: 64.03 )
Ranked among companies with meaningful EV-to-EBIT only.
GLPG' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.7  Med: -13.5 Max: 68.1
Current: 64.03
-47.7
68.1
EV-to-EBITDA 58.50
GLPG's EV-to-EBITDA is ranked lower than
74% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. GLPG: 58.50 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLPG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -53.4  Med: -14.2 Max: 62.2
Current: 58.5
-53.4
62.2
EV-to-Revenue 19.31
GLPG's EV-to-Revenue is ranked lower than
56% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. GLPG: 19.31 )
Ranked among companies with meaningful EV-to-Revenue only.
GLPG' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.6  Med: 23.1 Max: 48.2
Current: 19.31
6.6
48.2
Current Ratio 9.83
GLPG's Current Ratio is ranked higher than
72% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. GLPG: 9.83 )
Ranked among companies with meaningful Current Ratio only.
GLPG' s Current Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.86 Max: 10.67
Current: 9.83
1.16
10.67
Quick Ratio 9.83
GLPG's Quick Ratio is ranked higher than
73% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. GLPG: 9.83 )
Ranked among companies with meaningful Quick Ratio only.
GLPG' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 2.82 Max: 10.66
Current: 9.83
1.15
10.66
Days Sales Outstanding 37.65
GLPG's Days Sales Outstanding is ranked higher than
53% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. GLPG: 37.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLPG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 7.05  Med: 18.68 Max: 114.23
Current: 37.65
7.05
114.23

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.80
GLPG's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. GLPG: -15.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLPG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -51.6  Med: -8.25 Max: -2.2
Current: -15.8
-51.6
-2.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.39
GLPG's Price-to-Net-Cash is ranked higher than
65% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. GLPG: 4.39 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GLPG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.7  Med: 4.35 Max: 8.31
Current: 4.39
2.7
8.31
Price-to-Net-Current-Asset-Value 4.28
GLPG's Price-to-Net-Current-Asset-Value is ranked higher than
65% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. GLPG: 4.28 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GLPG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 4.01 Max: 7.59
Current: 4.28
2.43
7.59
Price-to-Tangible-Book 3.95
GLPG's Price-to-Tangible-Book is ranked higher than
57% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. GLPG: 3.95 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GLPG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.9  Med: 3.42 Max: 6.2
Current: 3.95
1.9
6.2
Price-to-Intrinsic-Value-Projected-FCF 4.52
GLPG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
99.99% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. GLPG: 4.52 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GLPG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 3.64  Med: 3.93 Max: 7.9
Current: 4.52
3.64
7.9
Price-to-Median-PS-Value 1.00
GLPG's Price-to-Median-PS-Value is ranked higher than
69% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. GLPG: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLPG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 0.92 Max: 1.87
Current: 1
0.52
1.87
Earnings Yield (Greenblatt) % 1.58
GLPG's Earnings Yield (Greenblatt) % is ranked higher than
80% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. GLPG: 1.58 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLPG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -17.7  Med: -4.8 Max: 3.2
Current: 1.58
-17.7
3.2

More Statistics

Revenue (TTM) (Mil) $163.07
EPS (TTM) $ -0.71
Beta1.56
Short Percentage of Float0.00%
52-Week Range $57.16 - 103.54
Shares Outstanding (Mil)50.87 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 124 134 134 205
EPS ($) -3.72 -4.65 -5.97 -5.78
EPS without NRI ($) -3.72 -4.65 -5.97 -5.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}